The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Projections of primary liver cancer to 2030 in 30 countries worldwide
Open accessAbstract
Primary liver cancer (PLC) is the sixth most common cancer worldwide and the second most common cause of cancer death. Future predictions can inform health planners and raise awareness of the need for cancer control action. We predicted the future burden of PLC in 30 countries around 2030. Incident cases of PLC (International Classification of Diseases, Tenth Revision, C22) were obtained from 30 countries for 1993‐2007. We projected new PLC cases to 2030 using age‐period‐cohort models (NORDPRED software). Age‐standardized incidence rates per 100,000 person‐years were calculated by country and sex. Increases in new cases and rates of PLC are projected in both sexes. The largest increases in rates are, among men, in Norway (2.9% per annum), US whites (2.6%), and Canada (2.4%) and, among women, in the United States (blacks 4.0%), Switzerland (3.4%), and Germany (3.0%). The projected declines are in China, Japan, Singapore, and parts of Europe (e.g., Estonia, Czech Republic, Slovakia). A 35% increase in the number of new cases annually is expected compared to 2005. This increasing burden reflects both increasing rates (and the underlying prevalence of risk factors) and demographic changes. Japan is the only country with a predicted decline in the net number of cases and annual rates by 2030. Conclusion: Our reporting of a projected increase in PLC incidence to 2030 in 30 countries serves as a baseline for anticipated declines in the longer term through the control of hepatitis B virus and hepatitis C virus infections by vaccination and treatment; however, the prospect that rising levels of obesity and its metabolic complications may lead to an increased risk of PLC that potentially offsets these gains is a concern. (H epatology 2018;67:600‐611).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2004) · The Lancet · doi:10.1016/s0140-6736(03)15268-3 · Cited by 12,717
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Vos, T., Barber, R. M., Bell, B., Bertozzi-Villa, A., Biryukov, S., Bolliger, I., Charlson, F., Davis, A., Degenhardt, L., Dicker, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60692-4 · Cited by 6,414
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
Schweitzer, A., Horn, J., Mikolajczyk, R. T., Krause, G., & Ott, J. J. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61412-x · Cited by 2,742
Mohd Hanafiah, K., Groeger, J., Flaxman, A. D., & Wiersma, S. T. (2013) · Hepatology · doi:10.1002/hep.26141 · Cited by 2,515
Williams, J. H., Phillips, T. D., Jolly, P. E., Stiles, J. K., Jolly, C. M., & Aggarwal, D. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/80.5.1106 · Cited by 1,781
The nutrition transition: worldwide obesity dynamics and their determinants
Popkin, B. M., & Gordon-Larsen, P. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802804 · Cited by 1,538
Cited by
Epidemiology of Hepatocellular Carcinoma
McGlynn, K. A., Petrick, J. L., & El‐Serag, H. B. (2021) · Hepatology · doi:10.1002/hep.31288 · Cited by 2,147
Self-citationAASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052
“The strongest risk factor for developing HCC is cirrhosis from any liver disease etiology, which is present in over 80% of patients with HCC. [7] Patients with cirrhosis from any etiology typically have a ∼ 2% annual risk of developing HCC. [8] Chronic hepatitis B virus (HBV) and hepatitis C virus…”
Epidemiology and surveillance for hepatocellular carcinoma: New trends
Singal, A. G., Lampertico, P., & Nahon, P. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.025 · Cited by 1,102
Yoon, S. M., Ryoo, B.-Y., Lee, S. J., Kim, J. H., Shin, J. H., An, J. H., Lee, H. C., & Lim, Y.-S. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5847 · Cited by 446
Haldar, D., Kern, B., Hodson, J., Armstrong, M. J., Adam, R., Berlakovich, G., Fritz, J., Feurstein, B., Popp, W., Karam, V., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.011 · Cited by 313
Metadata
- Authors
- Valery, P. C., Laversanne, M., Clark, P. J., Petrick, J. L., McGlynn, K. A., & Bray, F.
- Venue
- Hepatology
- Published
- 2017-12-23
- Volume
- 67
- Issue
- 2
- Pages
- 600-611
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2751640563
- Cited by
- 330
- References
- 41
- FWCI
- 8.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Projections of primary liver cancer to 2030 in 30 countries worldwide. https://app.cochat.ai/papers/10.1002/hep.29498
- The paper
- Valery, P. C., Laversanne, M., Clark, P. J., Petrick, J. L., McGlynn, K. A., & Bray, F. (2018). Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology. https://doi.org/10.1002/hep.29498
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.